ArticleNature and science of sleep2025
Exploring the Top 50 Drugs Associated with Restless Legs Syndrome Based on the FDA Data from 2004 to 2024.
Article in Nature and science of sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program.The international journal of neuropsychopharmacology · 2026Article
- Restless Legs Syndrome: A Network Model of Iron-Dependent Neuromodulation-A Narrative Review.Brain sciences · 2026Review
- Restless Legs Syndrome Associated With Fexofenadine Use: A Case Report.Clinical case reports · 2026Article
- Pharmacovigilance assessment of drug-induced aplastic anemia: analysis of the FDA adverse event reporting system.International journal of clinical pharmacy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drugs-associated restless legs syndrome(RLS) can significantly impact patients' quality of life. This study aims to identify the 50 most common drugs-associated with RLS in the FDA Adverse Event Reporting System (FAERS) database and track its epidemiological characteristics. Methods: We extracted reports of adverse drug events related to restless legs syndrome from the FAERS database, covering the period from Q1 2004 to Q3 2024. We compiled a list of the 50 most frequently reported drugs based on RLS reports. Four risk signal detection methods were employed to assess whether valid signals were triggered by these drugs: Reporting Odds Ratio, Proportional Reporting Ratio, Multi-item Gamma Poisson Shrinker, and Information Component from the Bayesian Confidence Propagation Neural Network. Logistic regression evaluated risk factors, and the Weibull Shape Parameter (WSP) test analyzed time-to-onset (TTO). Results: A total of 16,410 reports were linked to RLS, with sodium oxybate being the most common (648 cases, 3.9%). Nervous system medications comprised 31.3% of cases. Of the 50 drugs, 27 showed valid risk signals; only 6 were consistent with FDA labels. Risk factors included age under 44, weight over 64 kg, female gender, and 24 specific drugs. TTO analysis revealed that most drugs exhibited early onset patterns. Conclusion: Our study highlights drugs potentially linked to drug-associated RLS emphasizing the need to consider these risks in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.